FDA Expands Approval for Bladder Cancer Drug Anktiva
The agency now permits the use of Anktiva for high-grade papillary-only non-muscle invasive bladder cancer.
Updated on Oct. 29, 2026 in Cancer
Live Poll
Should the FDA use evidence from related diseases to approve new treatments faster?
The FDA has granted expanded approval for the drug Anktiva, allowing it to be used in treating patients with BCG-unresponsive, high-grade papillary-only non-muscle invasive bladder cancer. The treatment, developed by Altor BioScience LLC, is administered in combination with Bacillus Calmette-Guérin.
Why it matters
This approval allows more patients to access a treatment option for a difficult-to-treat form of bladder cancer where tumors form finger-like projections. The FDA based this decision on clinical similarities between high-grade papillary-only disease and carcinoma in situ.
In clinical trial NCT03022825, 62% of participants achieved a complete response, with 58% maintaining the response for 12 months. Anktiva is administered weekly via catheter for six weeks, with treatment potentially lasting up to 37 months.
The players
FDA
The federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.
Altor BioScience LLC
This biotechnology company focuses on the development of immunotherapies for the treatment of cancer and infectious diseases.
The details
Anktiva, also known as nogapendekin alfa inbakicept-pmln, works alongside Bacillus Calmette-Guérin to treat cancer cells directly in the bladder. Patients should be aware of potential side effects including urinary pain, urgency, blood in the urine, and systemic symptoms like fever or muscle aches.
Timeline
The FDA announced the expanded approval on October 29, 2026.
Health Landscape
This approval bridges a gap in the FDA development pathway for BCG-unresponsive non-muscle invasive bladder cancer drugs. By acknowledging the clinical parallels between different bladder cancer subtypes, the agency is evolving its regulatory framework for high-grade diseases.
Patients diagnosed with this specific type of bladder cancer now have a newly approved combination therapy to discuss with their oncologists. Treatment involves a commitment to weekly catheter-based administration over a six-week period, with ongoing monitoring for side effects.
The takeaway
Patients should consult with their healthcare providers to understand how this new approval fits into their specific treatment plans. Monitoring for potential side effects such as urinary tract infections or joint pain remains an essential part of the care process.
Further reading
For more information on current treatment trends, visit the Cancer section.
Source note: This article includes information reported by Fairhope Film Festival announces itinerary for 2025 - Gulf Coast Media.
Live Poll
Should the FDA use evidence from related diseases to approve new treatments faster?
